Clovis Oncology Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boulder, CO USA
Total Funding:$145M
Lead Investor(s):J. P. Morgan Securities LLC, BofA Merrill Lynch

Estimated Revenue & Financials

  • Clovis Oncology's estimated annual revenue is currently $95.4M per year.(?)
  • Clovis Oncology received $445.0M in venture funding in April 2018.
  • Clovis Oncology's estimated revenue per employee is $212,445
  • Clovis Oncology's total funding is $145M.

Employee Data

  • Clovis Oncology has 449 Employees.(?)
  • Clovis Oncology grew their employee count by -14% last year.
  • Clovis Oncology currently has 15 job openings.

We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, companion diagnostics intended to direct a compound in development to the population that is most likely to benefit from its use. Our first commercial product and lead product candidate, Rubraca® (rucaparib) tablets, is an oral, small molecule poly ADP-ribose polymerase, or PARP, inhibitor of PARP1, PARP2 and PARP3. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, lung and bladder cancers. Clovis holds worldwide rights for Rubraca. In the United States, Rubraca is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Rubraca is also approved in the United States for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Rubraca is an unlicensed medical product outside of the U.S. In addition, we have two other product candidates: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR). We maintain certain development and commercialization rights for lucitanib and global development and commercialization rights for rociletinib.